Abraham Ceesay - 08 Sep 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: President
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 08 Sep 2022
Net transactions value: -$371,329
Form type: 4
Filing time: 12 Sep 2022, 16:24:19 UTC
Previous filing: 24 Aug 2022
Next filing: 08 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$252,996	+19,210		$13.17	19,210	08 Sep 2022	Direct	F1
transaction	CERE	Common Stock	Sale	$624,325	-19,210	-100%	$32.50	0	08 Sep 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-19,210	-5%	$0.000000	365,009	08 Sep 2022	Common Stock	19,210	$13.17	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person.
F2	25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.